Global Endogenous Peptide Substances Market Research Report 2024

Publication ID:

PB508248364

Publication Date:

August 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Endogenous Peptide Substances market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
This report aims to provide a comprehensive presentation of the global market for Endogenous Peptide Substances, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endogenous Peptide Substances.
Report Scope
The Endogenous Peptide Substances market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Endogenous Peptide Substances market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Endogenous Peptide Substances companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides
Segment by Application
Research
Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Endogenous Peptide Substances companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endogenous Peptide Substances Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Neuropeptides
1.2.3 Hormones
1.2.4 Cytokines
1.2.5 Peptide Hormones
1.2.6 Bioactive Peptides
1.3 Market by Application
1.3.1 Global Endogenous Peptide Substances Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Research
1.3.3 Medicine
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Endogenous Peptide Substances Market Perspective (2019-2030)
2.2 Endogenous Peptide Substances Growth Trends by Region
2.2.1 Global Endogenous Peptide Substances Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Endogenous Peptide Substances Historic Market Size by Region (2019-2024)
2.2.3 Endogenous Peptide Substances Forecasted Market Size by Region (2025-2030)
2.3 Endogenous Peptide Substances Market Dynamics
2.3.1 Endogenous Peptide Substances Industry Trends
2.3.2 Endogenous Peptide Substances Market Drivers
2.3.3 Endogenous Peptide Substances Market Challenges
2.3.4 Endogenous Peptide Substances Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Endogenous Peptide Substances Players by Revenue
3.1.1 Global Top Endogenous Peptide Substances Players by Revenue (2019-2024)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Players (2019-2024)
3.2 Global Endogenous Peptide Substances Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Endogenous Peptide Substances Revenue
3.4 Global Endogenous Peptide Substances Market Concentration Ratio
3.4.1 Global Endogenous Peptide Substances Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endogenous Peptide Substances Revenue in 2023
3.5 Endogenous Peptide Substances Key Players Head office and Area Served
3.6 Key Players Endogenous Peptide Substances Product Solution and Service
3.7 Date of Enter into Endogenous Peptide Substances Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Endogenous Peptide Substances Breakdown Data by Type
4.1 Global Endogenous Peptide Substances Historic Market Size by Type (2019-2024)
4.2 Global Endogenous Peptide Substances Forecasted Market Size by Type (2025-2030)
5 Endogenous Peptide Substances Breakdown Data by Application
5.1 Global Endogenous Peptide Substances Historic Market Size by Application (2019-2024)
5.2 Global Endogenous Peptide Substances Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Endogenous Peptide Substances Market Size (2019-2030)
6.2 North America Endogenous Peptide Substances Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Endogenous Peptide Substances Market Size by Country (2019-2024)
6.4 North America Endogenous Peptide Substances Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Endogenous Peptide Substances Market Size (2019-2030)
7.2 Europe Endogenous Peptide Substances Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Endogenous Peptide Substances Market Size by Country (2019-2024)
7.4 Europe Endogenous Peptide Substances Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Endogenous Peptide Substances Market Size (2019-2030)
8.2 Asia-Pacific Endogenous Peptide Substances Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Endogenous Peptide Substances Market Size by Region (2019-2024)
8.4 Asia-Pacific Endogenous Peptide Substances Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Endogenous Peptide Substances Market Size (2019-2030)
9.2 Latin America Endogenous Peptide Substances Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Endogenous Peptide Substances Market Size by Country (2019-2024)
9.4 Latin America Endogenous Peptide Substances Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Endogenous Peptide Substances Market Size (2019-2030)
10.2 Middle East & Africa Endogenous Peptide Substances Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Endogenous Peptide Substances Market Size by Country (2019-2024)
10.4 Middle East & Africa Endogenous Peptide Substances Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Detail
11.1.2 Assertio Therapeutics Inc. Business Overview
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Introduction
11.1.4 Assertio Therapeutics Inc. Revenue in Endogenous Peptide Substances Business (2019-2024)
11.1.5 Assertio Therapeutics Inc. Recent Development
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Detail
11.2.2 Cipher Pharmaceuticals Inc. Business Overview
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Introduction
11.2.4 Cipher Pharmaceuticals Inc. Revenue in Endogenous Peptide Substances Business (2019-2024)
11.2.5 Cipher Pharmaceuticals Inc. Recent Development
11.3 Endo International Plc
11.3.1 Endo International Plc Company Detail
11.3.2 Endo International Plc Business Overview
11.3.3 Endo International Plc Endogenous Peptide Substances Introduction
11.3.4 Endo International Plc Revenue in Endogenous Peptide Substances Business (2019-2024)
11.3.5 Endo International Plc Recent Development
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Detail
11.4.2 Biosynth Carbosynth Business Overview
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Introduction
11.4.4 Biosynth Carbosynth Revenue in Endogenous Peptide Substances Business (2019-2024)
11.4.5 Biosynth Carbosynth Recent Development
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Detail
11.5.2 Lannett Co. Inc. Business Overview
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Introduction
11.5.4 Lannett Co. Inc. Revenue in Endogenous Peptide Substances Business (2019-2024)
11.5.5 Lannett Co. Inc. Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Endogenous Peptide Substances Introduction
11.6.4 Pfizer Revenue in Endogenous Peptide Substances Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Endogenous Peptide Substances Introduction
11.7.4 Johnson & Johnson Revenue in Endogenous Peptide Substances Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Peptide Institute
11.8.1 Peptide Institute Company Detail
11.8.2 Peptide Institute Business Overview
11.8.3 Peptide Institute Endogenous Peptide Substances Introduction
11.8.4 Peptide Institute Revenue in Endogenous Peptide Substances Business (2019-2024)
11.8.5 Peptide Institute Recent Development
11.9 Abbexa
11.9.1 Abbexa Company Detail
11.9.2 Abbexa Business Overview
11.9.3 Abbexa Endogenous Peptide Substances Introduction
11.9.4 Abbexa Revenue in Endogenous Peptide Substances Business (2019-2024)
11.9.5 Abbexa Recent Development
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Detail
11.10.2 Phoenix Pharmaceuticals Business Overview
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Introduction
11.10.4 Phoenix Pharmaceuticals Revenue in Endogenous Peptide Substances Business (2019-2024)
11.10.5 Phoenix Pharmaceuticals Recent Development
11.11 Creative Peptides
11.11.1 Creative Peptides Company Detail
11.11.2 Creative Peptides Business Overview
11.11.3 Creative Peptides Endogenous Peptide Substances Introduction
11.11.4 Creative Peptides Revenue in Endogenous Peptide Substances Business (2019-2024)
11.11.5 Creative Peptides Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂